EVANGELINE SMITH — Lobbyist Profile | Poliscope

EVANGELINE SMITH

Filings

Clients

Firms

Years active

2020–2026

Associated filing income

$330,000

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
EMERGEX VACCINES HOLDING LTD.	9	2020–2022
REALTA LIFE SCIENCES, INC.	9	2025–2026
PREACTIVE TECHNOLOGIES, INC.	4	2020
KIRIN BIOMATERIALS	3	2026

Lobbying firms

Firm	Filings	Years
THE CONAFAY GROUP, LLC	25	2020–2026

Original LDA source filings (25)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC

2026 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

Support for novel HIE therapeutics.

HCR

Health Issues

Patient access to novel HIE therapeutics.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

KIRIN BIOMATERIALS via

Source: Senate LDA

Show 21 more original filings

KIRIN BIOMATERIALS via THE CONAFAY GROUP, LLC

2026 · second_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MAN

Manufacturing

Support for the manufacture of bulk pharmaceuticals.

REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC

2026 · first_quarter · Q1

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

Support for novel HIE therapeutics.

HCR

Health Issues

Patient access to novel HIE therapeutics.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC

2025 · fourth_quarter · Q4

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Patient access to novel HIE therapeutics.

BUD

Budget/Appropriations

Support for novel HIE therapeutics.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC

2025 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Patient access to novel HIE therapeutics.

BUD

Budget/Appropriations

Support for novel HIE therapeutics.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC

2025 · second_quarter · 2A

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Patient access to novel HIE therapeutics.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC

2025 · first_quarter · 1A

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Patient access to novel HIE therapeutics.

SCI

Science/Technology

Patient access to novel HIE therapeutics.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC

2025 · second_quarter · Q2

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Patient access to novel HIE therapeutics.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC

2025 · first_quarter · Q1

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Patient access to novel HIE therapeutics.

SCI

Science/Technology

Patient access to novel HIE therapeutics.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

EMERGEX VACCINES HOLDING LTD. via THE CONAFAY GROUP, LLC

2022 · third_quarter · Q3

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Infectious disease, influenza and respiratory disease research

EMERGEX VACCINES HOLDING LTD. via THE CONAFAY GROUP, LLC

2022 · second_quarter · Q2

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Infectious disease, influenza and respiratory disease research

EMERGEX VACCINES HOLDING LTD. via THE CONAFAY GROUP, LLC

2022 · first_quarter · Q1

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Infectious disease, influenza and respiratory disease research

EMERGEX VACCINES HOLDING LTD. via THE CONAFAY GROUP, LLC

2021 · fourth_quarter · Q4

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Infectious disease, influenza and respiratory disease research

EMERGEX VACCINES HOLDING LTD. via THE CONAFAY GROUP, LLC

2021 · third_quarter · Q3

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Infectious disease, influenza and respiratory disease research

Filing targets: HOUSE OF REPRESENTATIVES

PREACTIVE TECHNOLOGIES, INC. via THE CONAFAY GROUP, LLC

2020 · third_quarter · Q3

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Traumatic Brain Injury Prevention

Filing targets: SENATE

EMERGEX VACCINES HOLDING LTD. via THE CONAFAY GROUP, LLC

2020 · third_quarter · Q3

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Influenza and respiratory disease research

Filing targets: SENATE

PREACTIVE TECHNOLOGIES, INC. via THE CONAFAY GROUP, LLC

2020 · second_quarter · Q2

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Traumatic Brain Injury Prevention

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

EMERGEX VACCINES HOLDING LTD. via THE CONAFAY GROUP, LLC

2020 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Influenza and respiratory disease research

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PREACTIVE TECHNOLOGIES, INC. via THE CONAFAY GROUP, LLC

2020 · first_quarter · Q1

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Traumatic Brain Injury Prevention

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

EMERGEX VACCINES HOLDING LTD. via THE CONAFAY GROUP, LLC

2020 · first_quarter · Q1

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Influenza and respiratory disease research

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PREACTIVE TECHNOLOGIES, INC. via THE CONAFAY GROUP, LLC

2020 · first_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

TBI prevention

EMERGEX VACCINES HOLDING LTD. via THE CONAFAY GROUP, LLC

2020 · first_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Influenza research.